{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:19:41Z","timestamp":1771337981224,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T20:13:48Z","timestamp":1462652028000},"page":"3191-3198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Intranasal hydroxypropyl-\u03b2-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection"],"prefix":"10.1016","volume":"34","author":[{"given":"Takato","family":"Kusakabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ozasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Kobari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Momota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Kishishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Kobiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsushi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3872","authenticated-orcid":false,"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.04.001_bib0190","series-title":"Influenza (seasonal) fact report","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0200","doi-asserted-by":"crossref","first-page":"e1000161","DOI":"10.1371\/journal.ppat.1000161","article-title":"Evolutionary dynamics and emergence of panzootic H5N1 influenza viruses","volume":"4","author":"Vijaykrishna","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0205","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vaccine.2011.11.003","article-title":"New insights in mucosal vaccine development","volume":"30","author":"Pavot","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0220","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/17425247.2015.1044435","article-title":"Nasal and pulmonary vaccine delivery using particulate carriers","volume":"12","author":"Jia","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0225","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","article-title":"Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract","volume":"173","author":"Renegar","year":"2004","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0230","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0235","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1016\/j.vaccine.2012.04.109","article-title":"Mucosal IgA responses in influenza virus infections; thoughts for vaccine, design","volume":"30","author":"van Riet","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7883\/yoken.JJID.2005.195","article-title":"Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines","volume":"58","author":"Tamura","year":"2005","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0245","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0753-3322(00)89027-7","article-title":"Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review","volume":"54","author":"Boyce","year":"2000","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0250","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0255","doi-asserted-by":"crossref","first-page":"e0139916","DOI":"10.1371\/journal.pone.0139916","article-title":"Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells","volume":"10","author":"Kim","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0260","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/S0264-410X(02)00155-X","article-title":"A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants","volume":"20","author":"Fujihashi","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0265","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0270","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMp048006","article-title":"Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy","volume":"350","author":"Couch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0275","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nbt.2344","article-title":"Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens","volume":"30","author":"Wegmann","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2013.66","article-title":"Airway structural cells regulate TLR5-mediated mucosal adjuvant, activity","volume":"7","author":"Van Maele","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0285","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2013.11.013","article-title":"Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine","volume":"174","author":"Patil","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0290","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/irv.12124","article-title":"Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses","volume":"7","author":"Kimoto","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0295","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1016\/j.vaccine.2011.09.033","article-title":"Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza","volume":"29","author":"Gupta","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0300","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1016\/j.vaccine.2009.04.074","article-title":"PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants","volume":"27","author":"Ichinohe","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0305","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0310","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/17425247.2.1.335","article-title":"Cyclodextrins in drug delivery","volume":"2","author":"Loftsson","year":"2005","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0320","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.1021\/cr500081p","article-title":"Review: a history of cyclodextrins","volume":"114","author":"Crini","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0325","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.4049\/jimmunol.1402027","article-title":"Hydroxypropyl-beta-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen","volume":"194","author":"Onishi","year":"2015","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0330","first-page":"168","article-title":"Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination","volume":"2","author":"Jounai","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2215","article-title":"How dying cells alert the immune system to danger","volume":"8","author":"Kono","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0340","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/nm.2403","article-title":"DNA released from dying host cells mediates aluminum adjuvant activity","volume":"17","author":"Marichal","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0345","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.vaccine.2015.01.013","article-title":"Compound 48\/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice","volume":"33","author":"Zeng","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0350","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/j.vaccine.2011.05.026","article-title":"Bis-(3\u2032,5\u2032)-cyclic dimeric adenosine monophosphate: strong Th1\/Th2\/Th17 promoting mucosal adjuvant","volume":"29","author":"Ebensen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0355","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.vaccine.2011.10.093","article-title":"A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging","volume":"30","author":"Asanuma","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0360","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/S0264-410X(03)00078-1","article-title":"Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia","volume":"21","author":"Ito","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0365","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.vaccine.2016.04.001_bib0370","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T08:11:45Z","timestamp":1718525505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":37,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16301219"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal hydroxypropyl-\u03b2-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}